Bakris, George L.

Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Clase, C. M., Carrero, J.-J., Ellison, D. H., Grams, M. E., Hemmelgarn, B. R., Jardine, M. J., Kovesdy, C. P., Kline, G. A., Lindner, G., Obrador, G. T., et al. (2020) · Kidney International

Potassium and Related DisordersParathyroid Disorders and Treatments

Cited by 498

Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial

Bakris, G. L., Pitt, B., Weir, M. R., Freeman, M. W., Mayo, M. R., Garza, D., Stasiv, Y., Zawadzki, R., Berman, L., & Bushinsky, D. A. (2015) · JAMA

Potassium and Related DisordersParathyroid Disorders and Treatments

Cited by 441

Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy

Bakris, G. L., Copley, J. B., Vicknair, N., Sadler, R., & Leurgans, S. (1996) · Kidney International

Chronic Kidney Disease and DiabetesBlood Pressure and Hypertension Studies

Cited by 417

Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria

Neuen, B. L., Heerspink, H. J. L., Vart, P., Claggett, B. L., Fletcher, R. A., Arnott, C., de Oliveira Costa, J., Falster, M. O., Pearson, S.-A., Mahaffey, K. W., et al. (2024) · Circulation

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 358

Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus

Sacks, D. B., Arnold, M., Bakris, G. L., Bruns, D. E., Horvath, A. R., Lernmark, Å., Metzger, B. E., Nathan, D. M., & Kirkman, M. S. (2023) · Diabetes Care

Diabetes Management and ResearchClinical Laboratory Practices and Quality Control

Cited by 351

Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes

Filippatos, G., Anker, S. D., Agarwal, R., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Schloemer, P., Tornus, I., Joseph, A., et al. (2021) · Circulation

Chronic Kidney Disease and DiabetesHormonal Regulation and Hypertension

Cited by 294

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results From the Randomized CREDENCE Trial

Mahaffey, K. W., Jardine, M. J., Bompoint, S., Cannon, C. P., Neal, B., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., et al. (2019) · Circulation

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 291

Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial

Nissen, S. E., Wolski, K. E., Prcela, L., Wadden, T., Buse, J. B., Bakris, G., Perez, A., & Smith, S. R. (2016) · JAMA

Pharmacology and Obesity TreatmentBariatric Surgery and Outcomes

Cited by 273

Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function: Data From the CANVAS Program

Neuen, B. L., Ohkuma, T., Neal, B., Matthews, D. R., de Zeeuw, D., Mahaffey, K. W., Fulcher, G., Desai, M., Li, Q., Deng, H., et al. (2018) · Circulation

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 257

Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER

Shaman, A. M., Bain, S. C., Bakris, G. L., Buse, J. B., Idorn, T., Mahaffey, K. W., Mann, J. F. E., Nauck, M. A., Rasmussen, S., Rossing, P., et al. (2022) · Circulation

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 255

Cardiovascular Events During Differing Hypertension Therapies in Patients With Diabetes

Weber, M. A., Bakris, G. L., Jamerson, K., Weir, M., Kjeldsen, S. E., Devereux, R. B., Velazquez, E. J., Dahlöf, B., Kelly, R. Y., Hua, T. A., et al. (2010) · Journal of the American College of Cardiology

Blood Pressure and Hypertension StudiesChronic Kidney Disease and Diabetes

Cited by 244

The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease

Rossing, P., Baeres, F. M. M., Bakris, G., Bosch-Traberg, H., Gislum, M., Gough, S. C. L., Idorn, T., Lawson, J., Mahaffey, K. W., Mann, J. F. E., et al. (2023) · Nephrology Dialysis Transplantation

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 242

The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study rationale, design, and baseline characteristics

Jardine, M. J., Mahaffey, K. W., Neal, B., Agarwal, R., Bakris, G. L., Brenner, B. M., Bull, S., Cannon, C. P., Charytan, D. M., de Zeeuw, D., et al. (2017) · American Journal of Nephrology

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 234

Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial

Kraus, B. J., Weir, M. R., Bakris, G. L., Mattheus, M., Cherney, D. Z. I., Sattar, N., Heerspink, H. J. L., Ritter, I., von Eynatten, M., Zinman, B., et al. (2021) · Kidney International

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 219

Effects of the Angiotensin Receptor Blocker Azilsartan Medoxomil Versus Olmesartan and Valsartan on Ambulatory and Clinic Blood Pressure in Patients With Stages 1 and 2 Hypertension

White, W. B., Weber, M. A., Sica, D., Bakris, G. L., Perez, A., Cao, C., & Kupfer, S. (2011) · Hypertension

Blood Pressure and Hypertension StudiesRenin-Angiotensin System Studies

Cited by 216

Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial

Mann, J. F. E., Rossing, P., Bakris, G., Belmar, N., Bosch-Traberg, H., Busch, R., Charytan, D. M., Hadjadj, S., Gillard, P., Górriz, J. L., et al. (2024) · Nature Medicine

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 200

The double challenge of resistant hypertension and chronic kidney disease

Rossignol, P., Massy, Z. A., Azizi, M., Bakris, G., Ritz, E., Covic, A., Goldsmith, D., Heine, G. H., Jager, K. J., Kanbay, M., et al. (2015) · The Lancet

Blood Pressure and Hypertension StudiesChronic Kidney Disease and Diabetes

Cited by 194

Epidemiology of hypertensive kidney disease

Udani, S., Lazich, I., & Bakris, G. L. (2011) · Nature Reviews Nephrology

Chronic Kidney Disease and DiabetesBlood Pressure and Hypertension Studies

Cited by 171

Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice

Oshima, M., Jardine, M. J., Agarwal, R., Bakris, G., Cannon, C. P., Charytan, D. M., de Zeeuw, D., Edwards, R., Greene, T., Levin, A., et al. (2021) · Kidney International

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 166

Prediction and Management of Hyperkalemia Across the Spectrum of Chronic Kidney Disease

Lazich, I., & Bakris, G. L. (2014) · Seminars in Nephrology

Potassium and Related DisordersChronic Kidney Disease and Diabetes

Cited by 164

Finerenone reduces new-onset atrial fibrillation in patients with chronic kidney disease and type 2 diabetes

Filippatos, G., Bakris, G. L., Pitt, B., Agarwal, R., Rossing, P., Ruilope, L. M., Butler, J., Lam, C. S. P., Kolkhof, P., Roberts, L., et al. (2021) · Journal of the American College of Cardiology

Atrial Fibrillation Management and OutcomesChronic Kidney Disease and Diabetes

Cited by 153

Chronic Kidney Disease as a Coronary Artery Disease Risk Equivalent

Briasoulis, A., & Bakris, G. L. (2013) · Current Cardiology Reports

Chronic Kidney Disease and DiabetesDialysis and Renal Disease Management

Cited by 152

EXamination of CArdiovascular OutcoMes with AlogliptIN versus Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE)

White, W. B., Bakris, G. L., Bergenstal, R. M., Cannon, C. P., Cushman, W. C., Fleck, P., Heller, S., Mehta, C., Nissen, S. E., Perez, A., et al. (2011) · American Heart Journal

Diabetes Treatment and ManagementStatistical Methods in Clinical Trials

Cited by 152

Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial

Weber, M. A., Jamerson, K., Bakris, G. L., Weir, M. R., Zappe, D., Zhang, Y., Dahlof, B., Velazquez, E. J., & Pitt, B. (2013) · The Lancet

Blood Pressure and Hypertension StudiesSodium Intake and Health

Cited by 150